NCT01248897View on ClinicalTrials.gov

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

CompletedOBSERVATIONAL
Enrollment

158

Participants

Timeline

Start Date

August 17, 2010

Primary Completion Date

December 1, 2013

Study Completion Date

September 5, 2014

Conditions
Neoplasms, Metastasis
Interventions
OTHER

This study is non-interventional study, so this section is not applicable.

This study is non-interventional study, so this section is not applicable.

Trial Locations (17)

1300

GSK Investigational Site, Pasay

169610

GSK Investigational Site, Singapore

Unknown

GSK Investigational Site, Hong Kong

GSK Investigational Site, Pokfulam

GSK Investigational Site, Tuenmen

GSK Investigational Site, Wan Chai

602-030

GSK Investigational Site, Busan

602-715

GSK Investigational Site, Busan

602-739

GSK Investigational Site, Busan

210-852

GSK Investigational Site, Gangwon-do

400-711

GSK Investigational Site, Incheon

410-769

GSK Investigational Site, Kyunggi-do

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Songpa-gu, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01248897 - Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib | Biotech Hunter | Biotech Hunter